Who are PANCRECARB® (pancrelipase)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pancreatic Enzyme, Panzytrat 25.000 FIP-E units of Lipase, Pancrelipase Capsules, creon 35.000 Ph.U (R), Creon® 10000, Pancreatic enzyme capsules.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pancrecarb-pancrelipase.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

PANCRECARB® (pancrelipase) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PANCRECARB® (pancrelipase) (PANCRECARB® (pancrelipase)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pancreatic enzyme replacement therapy. Area: Gastroenterology.

phase 3 Pancreatic enzyme replacement therapy Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

PANCRECARB® (pancrelipase) (PANCRECARB® (pancrelipase)) — Digestive Care, Inc.. Pancrelipase is a pancreatic enzyme replacement therapy that supplies lipase, protease, and amylase to aid digestion of fats, proteins, and carbohydrates in patients with pancreatic insufficiency.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
PANCRECARB® (pancrelipase) TARGET	PANCRECARB® (pancrelipase)	Digestive Care, Inc.	phase 3	Pancreatic enzyme replacement therapy
Pancreatic Enzyme	Pancreatic Enzyme	University of Oxford	marketed	Pancreatic enzyme replacement therapy (PERT)
Panzytrat 25.000 FIP-E units of Lipase	Panzytrat 25.000 FIP-E units of Lipase	Foundation for Liver Research	marketed	Pancreatic enzyme replacement therapy	Triglycerides and dietary lipids
Pancrelipase Capsules	Pancrelipase Capsules	Ohio State University	marketed	Pancreatic enzyme replacement therapy
creon 35.000 Ph.U (R)	creon 35.000 Ph.U (R)	Hospital Clinico Universitario de Santiago	marketed	Pancreatic enzyme replacement therapy
Creon® 10000	Creon® 10000	Abbott	phase 3	Pancreatic enzyme replacement therapy
Pancreatic enzyme capsules	Pancreatic enzyme capsules	Asian Institute of Gastroenterology, India	phase 3	Pancreatic enzyme replacement therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pancreatic enzyme replacement therapy class)

Abbott · 2 drugs in this class
Asian Institute of Gastroenterology, India · 1 drug in this class
Digestive Care, Inc. · 1 drug in this class
Foundation for Liver Research · 1 drug in this class
Hospital Clinico Universitario de Santiago · 1 drug in this class
Ohio State University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PANCRECARB® (pancrelipase) — Competitive Intelligence Brief. https://druglandscape.com/ci/pancrecarb-pancrelipase. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab